FDG PET/CT评估免疫治疗:应用机会与陷阱解读
免疫检查点阻断在多种癌症中产生持久缓解,但部分患者无效或出现严重免疫相关不良事件。传统解剖影像和肿瘤反应标准在早期评估方面存在局限。本文综述FDG PET/CT作为功能生物标志物在肿瘤反应评估和免疫相关不良事件评价中的应用,主要聚焦转移性黑色素瘤。
要点
- FDG PET/CT可提供肿瘤反应和免疫激活的无创功能生物标志物。
- 传统解剖影像和反应标准在免疫治疗早期评估中具有局限性。
- 本文综述FDG PET/CT在肿瘤反应评估和免疫相关不良事件评价中的应用。
核心结论
- FDG PET/CT作为无创功能生物标志物,有助于评估免疫检查点阻断治疗患者的肿瘤反应、预后和免疫激活。
研究设计与样本
- 本文为综述,讨论癌症免疫治疗的肿瘤学应用和影像需求,以及应用FDG PET/CT进行肿瘤反应评估和免疫相关不良事件评价的近期研究,主要聚焦转移性黑色素瘤。
主要发现
- 免疫检查点阻断可在多种癌症中产生持久缓解并显著影响标准治疗,但许多患者仍无反应或抗肿瘤反应持续时间有限。
- 免疫检查点阻断引起的免疫相关不良事件对部分患者可能严重且致衰弱,限制治疗继续并导致严重自身免疫状况。
- 标准解剖影像和肿瘤反应标准在充分评估肿瘤反应方面存在局限,尤其在治疗早期。
- 多项研究评估了FDG PET/CT在免疫检查点阻断治疗患者中用于评估预后、治疗反应和免疫激活。
临床怎么用
- 对于接受免疫检查点阻断治疗的患者,可考虑使用FDG PET/CT作为功能生物标志物辅助评估肿瘤反应和免疫激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint blockade has demonstrated the ability to modulate the immune system to produce durable responses in a wide range of cancers and has significantly impacted the standard of care. However, many cancer patients still do not respond to immune checkpoint blockade or have a limited duration of antitumor responses. Moreover, immune-related adverse events caused by immune checkpoint blockade can be severe and debilitating for some patients, limiting continuation of therapy and resulting in severe autoimmune conditions. Standard-of-care conventional anatomic imaging modalities and tumor response criteria have limitations to adequately assess tumor responses, especially early in the course of therapy, for risk-adapted clinical management to inform care of patients treated with immunotherapy. Molecular imaging with position emission tomography (PET) provides a noninvasive functional biomarker of tumor response, and of immune activation, for patients on immune-based therapies to help address these needs. 18F-FDG (FDG) PET/CT is readily available clinically and a number of studies have evaluated the use of this agent for assessment of prognosis, treatment response and immune activation for patients treated with immune checkpoint blockade. In this review paper, we discuss the current oncologic applications and imaging needs of cancer immunotherapy, recent studies applying FDG PET/CT for tumor response assessment, and evaluation of immune-related adverse events for improving clinical management. We largely focus on metastatic melanoma; however, we generalize where applicable to immunotherapy in other tumor types. We also briefly discuss PET imaging and quantitation as well as emerging non-FDG PET imaging radiotracers for cancer immunotherapy imaging.
引用
- Cho SY, Huff DT, Jeraj R, et al. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Semin Nucl Med. 2020. PMID: 33059821. doi:10.1053/j.semnuclmed.2020.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。